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Analysis of the Ribonuclease A 
superfamily of Antimicrobial 
peptides in patients Undergoing 
Chronic peritoneal Dialysis
Neha Dhingra pottanat1, Amy C. Brook  2, Maria Bartosova3, Hanna Cortado4, 
sudipti Gupta4, Birong Li4, Ashley R. Jackson  4, Martin Vonau5, shira Cohen4, Maria Ferrara6, 
Christina B. Ching4,7, John David spencer4,8, Annelie Brauner9, Donald J. Fraser2,10, Claus 
peter schmitt3, Matthias eberl2, Rose Ayoob11 & Brian Becknell4,8
Infectious peritonitis is a common complication in patients undergoing chronic peritoneal dialysis 
(pD), limiting the duration of pD as a modality for renal replacement therapy and increasing patient 
morbidity and mortality. Antimicrobial peptides (AMps) serve critical roles in mucosal defense, but 
their expression and activity during peritonitis are poorly understood. We hypothesized that AMps 
belonging to the Ribonuclease (RNase) A Superfamily are present in peritoneal fluid and increase during 
peritonitis in patients undergoing chronic PD. In the absence of peritonitis, we detected RNase 3, RNase 
6, and RNase 7 in cell-free supernatants and viable cells obtained from peritoneal fluid of chronic PD 
patients. The cellular sources of these RNases were eosinophils (RNase 3), macrophages (RNase 6), and 
mesothelial cells (RNase 7). During peritonitis, RNase 3 increased 55-fold and RNase 7 levels increased 
3-fold on average, whereas RNase 6 levels were unchanged. The areas under the receiver-operating 
characteristic curves for RNase 3 and RNase 7 were 0.99 (95% confidence interval (CI): 0.96–1.0) and 
0.79 (95% CI: 0.64–0.93), respectively, indicating their potential as biomarkers of peritonitis. Discrete 
omental reservoirs of these RNases were evident in patients with end stage kidney disease prior to pD 
initiation, and omental RNase 3 reactive cells increased in patients undergoing PD with a history of 
peritonitis. We propose that constitutive and inducible pools of antimicrobial RNases form a network to 
shield the peritoneal cavity from microbial invasion in patients undergoing chronic pD.
Peritoneal dialysis (PD) is a well-established modality of chronic renal replacement therapy worldwide, account-
ing for 11% of the overall dialysis population1. The duration of chronic PD is frequently limited by episodes 
of infectious peritonitis. Several risk factors leading to peritonitis have been addressed by modifying PD cath-
eter design and surgical techniques during catheter insertion2. Additional changes in connection techniques, 
catheter exit-site care, and patient training have reduced peritonitis rates over the last decade3–5. Despite these 
improvements, peritonitis is a principal reason for hospitalization, conversion to hemodialysis, and death in PD 
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patients6,7. In a recent study, preventing PD-related infections was identified as the top priority for PD patients 
and their caregivers8.
Further reductions in peritonitis rates may be achieved through strategies that enhance peritoneal innate 
immune defenses against invading microorganisms. Devising such strategies requires a more complete under-
standing of peritoneal defense mechanisms and how they are influenced by chronic kidney disease (CKD), PD, 
and peritonitis. The peritoneum is lined by mesothelial cells that possess innate defense mechanisms including: 
barrier function, constitutive secretion of antimicrobial mediators, and expression of pattern recognition recep-
tors that serve as microbial sensors9–11. Mesothelial cells are assisted by patrolling leukocytes, such as eosinophils 
and macrophages, and together these cells form an interactive network to coordinate a rapid and efficient innate 
immune response12,13.
Innate immune cells utilize a variety of antibacterial peptides and proteins to neutralize microbial invaders, 
including antimicrobial peptides (AMPs)14,15. AMPs may serve as novel antimicrobial agents16,17. In addition to 
their antimicrobial action, AMPs modulate the activity of epithelial and inflammatory cells, influencing diverse 
processes such as mitosis, wound healing, cytokine release, chemotaxis, protease-antiprotease balance, and redox 
homeostasis18. Defensins, Cathelicidin (LL-37), and Neutrophil Gelatinase-Associated Lipocalin (NGAL) are 
examples of AMPs that are present in the peritoneal cavity19–22.
The Ribonuclease (RNase) A Superfamily encodes multiple AMPs with potent microbicidal activity against 
Gram-positive, Gram-negative, and fungal organisms23–27. These antimicrobial RNases exhibit cell-specific 
expression patterns. Whereas RNase 3 and RNase 6 are produced by leukocytes, RNase 7 is constitutively secreted 
by epithelial cells of the skin, airway, and urinary tract23,28. In this study, we hypothesized that these antimicrobial 
RNases are present in the peritoneal cavity of patients undergoing chronic PD, where they are produced by spe-
cific cell populations and exhibit unique changes in expression following peritonitis.
Results
RNase 3,6, and 7 are present in peritoneal fluid of patients on chronic PD and differentially 
regulated during peritonitis. We investigated peritoneal fluid concentrations of RNase 3, 6, and 7 in a 
cohort of 27 patients undergoing chronic PD, comprising 21 adult and six pediatric patients (Table S1). At the 
time of peritoneal fluid collection, all patients lacked signs and symptoms of peritonitis. No patient experienced 
a peritonitis episode within the month preceding or following peritoneal fluid collection. RNase concentrations 
were measured in peritoneal fluid by enzyme linked immunosorbent assay (ELISA). All three antimicrobial 
RNases were detectable in all patients, with the exception of three pediatric patients who lacked RNase 3 protein 
expression (Fig. 1A). RNase 7 levels were significantly higher than RNase 3 or RNase 6 (Fig. 1A). Compared to 
adult patients, pediatric RNase 6 levels were lower and RNase 7 levels were higher (Fig. S1). Next, RNase con-
centrations were measured in peritoneal fluid samples from 21 adults and one pediatric patient with peritonitis. 
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Figure 1. Peritoneal fluid RNase concentrations in chronic PD patients in the absence of infection and 
following peritonitis. (A) In 27 uninfected, chronic PD patients, RNase 7 concentrations were increased, 
compared to RNase 3 and RNase 6. Lines indicate median and interquartile range. *Adjusted p < 0.0001, 
Kruskal-Wallis test with Dunn’s correction for multiple comparisons. (B–D) RNase 3, RNase 6, and RNase 
7 concentrations in 22 PD patients with peritonitis. Each patient’s RNase concentration during peritonitis is 
compared to that obtained in the absence of infection (**p < 0.0001, Wilcoxon matched-pairs signed rank test).
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Concentrations were compared to uninfected samples collected from the same individuals. During peritonitis, 
RNase 3 levels increased 55-fold on average (range 2–134), from a median value of 211 pg/ml (IQR 167–385) in 
uninfected fluid to 9977 pg/ml (IQR 3906–20,332) in peritonitis (Fig. 1B). In five adult patients who experienced 
recurrent peritonitis, RNase 3 concentration returned to uninfected levels when measured >3 months post-in-
fection and subsequently increased with the next peritonitis episode (Fig. S2). RNase 6 levels did not vary signif-
icantly between uninfected and peritonitis samples (Fig. 1C). RNase 7 levels increased 3-fold on average (range 
1–19), from a median value of 2071 pg/ml (IQR 1592–4628) in uninfected fluid to 6692 pg/ml (IQR 3080–8805) 
in adults with peritonitis (Fig. 1D). The areas under the receiver operator characteristics (ROC) curves for RNase 
3 and RNase 7 were 0.99 (95% CI, 0.97–1.0) and 0.79 (95% CI, 0.64–0.93), respectively (Fig. 2). There was no 
statistically significant relationship between RNase levels and the outcome of peritoneal fluid culture (i.e., culture 
negative, Gram-negative, or Gram-positive bacteria) in patients with peritonitis (data not shown).
Cellular sources of RNases in peritoneal fluid. We hypothesized that the presence of RNases in unin-
fected peritoneal fluid may be due to their local production by cells within the peritoneal cavity. We therefore iso-
lated viable cells from peritoneal fluid of six pediatric PD patients and measured RNASE3, RNASE6, and RNASE7 
mRNA levels by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). Pediatric patients are 
particularly well suited for these studies for two reasons: (1) Their underlying diseases are mostly restricted to the 
kidney and urinary tract; and (2) Children lack secondary pathologies often present in adults, such as changes 
related to long-standing hypertension, diabetes, smoking, and aging. In all cases, RNASE mRNA expression was 
detectable, and RNASE7 mRNA levels were more abundant than RNASE3 (Fig. 3A). We evaluated RNase pro-
tein expression by immunofluorescence microscopy and performed co-staining with lineage specific antibodies. 
Using a differential staining method, we detected mesothelial cells, monocytes, and eosinophils in peritoneal fluid 
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Figure 2. ROC curves identify RNase 3 and RNase 7 as potential biomarkers of peritonitis. AUC: Area under 
the ROC curve. *p < 0.0001 and **p = 0.0012.
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Figure 3. RNase expression by cells obtained from peritoneal fluid of uninfected pediatric PD patients. (A) 
RNASE3, RNASE6, and RNASE7 mRNA levels. Lines indicate median and interquartile range. #p = 0.0013; 
Kruskal-Wallis test with Dunn’s correction for multiple comparisons. (B–E) RNases exhibit cell-specific 
distribution in peritoneal fluid. The initial drain was collected prior to starting nightly CCPD and subject to 
cytocentrifugation. (B) Kwik-Diff staining identifies eosinophils (solid arrow), macrophages (dashed arrows) 
and mesothelial cells (arrowheads) in peritoneal fluid; (C) Granular distribution of RNase 3 in a CD66b(+) 
eosinophil; (D) RNase 6 reactivity and partial co-localization with CD68, a macrophage lineage marker; (E) 
Cytoplasmic staining of RNase 7 in a Cytokeratin (CK)(+) cluster of mesothelial cells. All figures are 40x 
original magnification. Scale bar: 25 microns. Representative images from at least 3 separate patients are shown.
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from these patients (Fig. 3B). We found that RNase 3, RNase 6, and RNase 7 localized exclusively to CD66b(+) 
eosinophils, CD68(+) monocytes, and Cytokeratin (CK)(+) mesothelial cells, respectively (Fig. 3C–E).
RNases localize to discrete cell types within human omentum. We investigated RNase distribution 
by immunohistochemistry in omentum from children with stage 5 CKD at the time of PD catheter insertion. The 
omentum is a highly vascularized structure composed of fibroadipose tissue that is lined with mesothelial cells 
(Fig. 4A). RNase 3 localized to leukocytes within omental blood vessels (Fig. 4B), while RNase 6 reactivity was 
restricted to occasional cells in the submesothelial space (Fig. 4C). RNase 7 uniquely localized to the mesothelial 
lining (Fig. 4D).
Since RNase 3 exhibited the greatest induction in peritoneal fluid during peritonitis (Fig. 1B), we also evalu-
ated the impact of peritonitis on the proportion of RNase 3 immunoreactive cells in omentum. For these studies, 
we utilized a registry of omental tissue from pediatric patients with normal kidney function, stage 5 CKD prior 
to dialysis initiation, and chronic PD with and without a history of peritonitis29. Using automated quantitative 
immunohistochemistry, we determined that omentum from patients with a history of peritonitis contained a 
greater proportion of RNase 3+ cells, compared to the other experimental groups (Fig. 5).
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Figure 4. Localization of RNases in omentum from children with stage 5 CKD. (A) H&E staining illustrates 
normal omental morphology. Arrows indicate mesothelium. Abundant capillaries are evident within the 
mesothelium. (B) RNase 3 is expressed by leukocytes (dashed arrows) in omental blood vessels. (C) RNase 
6 is expressed by rare interstitial cells (black arrowhead) in the submesothelial space near blood vessels (x). 
(D) RNase 7 is expressed by mesothelial cells. Scales bars indicate 32.5 microns (A) and 50 microns (B–D). 
Original magnification 60x (A) and 40x (B–D). Representative micrographs from 4 patients are shown. (E) 
Quantification of omental RNase+ cells. **p < 0.0001 Kruskal-Wallis test with Dunn’s correction for multiple 
comparisons.
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Figure 5. Impact of peritonitis on RNase 3 expression in pediatric omentum. (A) Sparse omental RNase 3+ 
cells (arrow) in PD patients without a history of peritonitis. (B) Widespread omental RNase 3+ cells following 
peritonitis (arrows). Both micrographs are 20x magnification. Scale bars indicate 20 μm. (C) Quantification of 
RNase 3+ cell frequency in children undergoing PD with a history of peritonitis, compared to indicated control 
populations (*p < 0.0001, Kruskal-Wallis test with Dunn’s correction for multiple comparisons; 9–10 patients/
group).
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Discussion
AMPs in the RNase A Superfamily exhibit potent, broad-spectrum antimicrobial activity toward microorganisms 
implicated in peritonitis in the chronic PD population5,25,26,30. In this study, we demonstrated the presence of 
RNase 3, RNase 6, and RNase 7 in the peritoneal fluid of patients receiving chronic PD who lacked clinical signs 
and symptoms of peritonitis. During peritonitis, we observed accumulation of RNase 3 and RNase 7 in peritoneal 
fluid. Immunolocalization studies in peritoneal fluid and omentum revealed distinct cellular reservoirs for each 
RNase. Collectively, these findings suggest roles for antimicrobial RNases in promoting antimicrobial immunity 
in patients undergoing chronic PD.
RNase 3 levels increase during peritonitis. Among the antimicrobial RNases evaluated in this study, 
RNase 3 exhibited the most consistent induction during peritonitis. RNase 3 induction occurred regardless of 
culture results, suggesting that the release of RNase 3 may be elicited by the host immune response rather than 
in response to a specific microbial cue. This is supported by a study that demonstrated RNase 3 release by eosin-
ophils in response to cytokine priming and the addition of platelet activating factor or complement factor C5a31. 
Increased RNase 3 levels may also reflect the degranulation or recruitment of eosinophils in PD patients with 
peritonitis, which contain large amounts of RNase 3 in cytoplasmic granules32. Neutrophils represent an alterna-
tive reservoir of RNase 3, and their brisk recruitment and degranulation may account for increased RNase 3 levels 
in peritonitis33–35. The average concentration of RNase 3 in infected peritoneal fluid is 3–4 orders of magnitude 
below the minimal inhibitory concentration of recombinant RNase 3 toward Gram-positive and Gram-negative 
bacteria (H.C. and B.B., unpublished observations)36,37. It is therefore unlikely that RNase 3 exerts significant 
bactericidal activity in peritoneal fluid. Rather, we and others have hypothesized that RNase 3 exerts antimicro-
bial activity intracellularly, i.e., toward ingested bacteria within the eosinophil’s phagosome28. Alternatively, it is 
possible that RNase 3 serves an immunomodulatory function. RNase 3 exhibits high-affinity binding to bacterial 
cell wall components such as peptidoglycan and lipopolysaccharide38. This binding neutralizes bacterial endo-
toxin and limits pro-inflammatory cytokine production by phagocytes39. This raises the possibility that increased 
RNase 3 levels may serve to dampen the local immune response and prevent septic shock syndrome. Further 
studies are required to clarify the biological significance of RNase 3 during peritonitis.
Mesothelial cells are a novel source of RNase 7. Whereas leukocyte populations appear to account for 
limited RNase 3 and RNase 6 expression in peritoneal fluid, mesothelial cells serve as the sole source of RNase 
7, which is the most abundant of the antimicrobial RNases evaluated in this study. The production of RNase 7 
by mesothelial cells is consistent with studies in the skin, airway, and urinary tract, which have demonstrated 
constitutive secretion of RNase7 by epithelial cells24,40–42. These studies have led to the hypothesis that RNase 7 
serves as an antimicrobial shield to prevent epithelial attachment and invasion by microorganisms43. Mesothelial 
cells express pattern recognition receptors and rapidly synthesize cytokines, chemokines, and AMPs in response 
to microbial exposure44,45. Chronic PD leads to mesothelial cell loss, and this depletion of mesothelial cells may 
lead to intraperitoneal deficiency in RNase 7 and increased peritonitis susceptibility46,47. Mesothelial loss as a 
consequence of chronic PD may account for absent induction of RNase 7 in certain patients with peritonitis. It is 
also noteworthy that RNase 7 levels were higher in children than adults in this study. The potential links between 
RNase 7 levels, patient age, mesothelial content, and peritonitis susceptibility warrant additional investigation.
Diagnostic utility of RNase 3 and RNase 7 as peritonitis biomarkers. The areas under the ROC 
curves for RNase 7 and particularly RNase 3 predict that they are good to excellent candidate biomarkers of 
peritonitis. Peritoneal fluid cell count, differential, gram stain, and culture are the current standard evaluation 
tools to diagnosis peritonitis in patients receiving chronic PD. Each dialysis center is required to maintain a 
culture-negative peritonitis rate of <20% to insure that the culture technique is adequate7. This highlights the 
attention to detail that dialysis centers need to maintain when evaluating patients with peritonitis and the need for 
improved diagnostic testing. Further, larger scale studies are required to determine whether the addition of RNase 
3 and RNase 7 measurement to standard evaluation methods increases the sensitivity and specificity of peritonitis 
diagnosis in the chronic PD patient population.
omentum is a rich source of RNase expressing cells. In this study, we implicate omental mesothelium 
and leukocytes as distinct cellular sources of AMPs belonging to the RNase A Superfamily. The RNases join a 
growing number of AMPs expressed by omentum, as omental adipocytes serve as sources of AMPs such as defen-
sins and cathelicidin48,49. When omentum was examined in patients with a history of peritonitis, we observed a 
greater proportion of RNase 3+ cells – even in instances where tissue was harvested 24 weeks after peritonitis. 
In this way, the omentum serves as a local reservoir of RNase 3+ cells that can rapidly mobilize in response to 
subsequent microbial exposure. The omentum is well-suited for this purpose, as omental high endothelial venules 
promote rapid neutrophil recruitment that protects mice with peritonitis from developing sepsis, and omental 
milky spots concentrate invading microorganisms where they are engulfed and killed by phagocytes50.
These antimicrobial properties of omentum are especially intriguing in the pediatric chronic PD population, 
as the six pediatric patients in our study had either a partial or complete omentectomy at the time of PD cath-
eter placement. Omentectomy is commonly performed in pediatric patients to reduce the risk of PD catheter 
malfunction51. Furthermore, pediatric PD patients represent a unique patient group to investigate the impact of 
PD and PD-associated peritonitis on the omentum, as the vast majority suffer from non-inflammatory diseases, 
mainly congenital urinary tract malformations. This lack of baseline inflammation increases the likelihood of a 
causal link between the observed increase in omental RNase 3+ cells and history of peritonitis in these patients.
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Conclusions
We have demonstrated the presence of multiple antimicrobial RNases with distinct cellular sources in the peri-
toneal fluid of patients undergoing chronic PD, which display unique expression patterns following peritonitis. 
Peritoneal fluid concentrations of RNase 3 and RNase 7 increase during peritonitis, and further studies are war-
ranted to test their efficacy as peritonitis biomarkers. Our data support a model in which a network of RNases 
helps to protect the peritoneal cavity from microbial invaders (Fig. 6). Mesothelial cells constitutively synthesize 
RNase 7, which acts as an antimicrobial shield at the surface of the peritoneal membrane. Sentinel leukocytes 
patrolling the peritoneal cavity and omentum express RNase 3 (eosinophils) and RNase 6 (monocytes/mac-
rophages). We predict that this local antimicrobial RNase network contributes substantially to the prevention and 
eradication of infectious peritonitis in the PD population.
Methods
Adult pD patients. This study was approved by the South East Wales Local Ethics Committee (04WSE04/27) 
and registered on the UK Clinical Research Network Study Portfolio under reference number #11838 “Patient 
immune responses to infection in PD”. All individuals provided written informed consent. All research was per-
formed in accordance with relevant guidelines and regulations. 21 adults receiving continuous ambulatory PD 
(CAPD) or continuous cycling PD (CCPD) at the University Hospital of Wales, Cardiff, between November 2013 
and March 2018 were followed for up to three years (Samples 1–21 in Table S1). Cell-free peritoneal effluent 
samples from ≥8 hour dwells were collected when the individuals were stable (with no infection in the previous 
month), and within 24 hours of presentation with acute peritonitis, before starting antibiotic treatment. Clinical 
diagnosis of acute peritonitis was based on the International Society of Peritoneal Dialysis (ISPD) Consensus 
Guidelines52. Patients experienced 1–5 episodes of peritonitis during the study period. Three peritonitis episodes 
were defined as culture-negative (after incubation of up to 5 days), and the remaining episodes were confirmed 
bacterial infections. Causative microorganisms are shown in Table S1. Cases of fungal infection and polymicro-
bial or unclear culture results were excluded from the study.
pediatric pD patients. Following approval of the Nationwide Children’s Hospital Institutional Review 
Board (Protocol IRB16-00086) and provision of informed consent from a parent and/or legal guardian, we 
recruited six chronic PD patients at Nationwide Children’s Hospital between March 2016 and September 2017 
(samples 22–27 in Table S1). All research was performed in accordance with relevant guidelines and regula-
tions. All patients underwent CCPD using dextrose-based (high-GDP) PD solution (Dianeal, Baxter, Deerfield, 
IL). Peritoneal fluid was collected from the patients after a long (≥8 hours) daytime dwell cycle prior to CCPD. 
All patients lacked signs and symptoms of peritonitis within the month preceding sample collection. Clinical 
diagnosis of acute peritonitis was based on the International Society of Peritoneal Dialysis (ISPD) Consensus 
Guidelines52.
Peritoneal fluid processing. Following centrifugation of peritoneal fluid (500 g, 10 minutes, 4 °C), the 
supernatant was stored at −80 °C for ELISA. The cellular pellet was resuspended in sterile phosphate buffered 
saline, and enumerated. Over 95% of cells recovered from PD fluid were viable based on trypan blue exclusion. 
The total number of live cells varied between 50,000 to 200,000. Cells were subsequently lysed in RNA or protein 
extraction buffer and frozen at −80 °C.
Figure 6. A network of RNases protects the peritoneum from microbial invasion. Mesothelial cells 
constitutively secrete RNase 7 (R7). Macrophages patrol the submesothelial space and synthesize RNase 6 (R6). 
Eosinophils circulate within the peritoneal microvasculature and produce RNase 3 (R3). In addition, both R3+ 
eosinophils and R6+ macrophages patrol the peritoneal cavity.
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pediatric omentum. Formalin-fixed, paraffin-embedded, deidentified human omentum from children with 
stage 5 CKD was provided with approval from the Nationwide Children’s Hospital Institutional Review Board 
in collaboration with the Department of Anatomic Pathology (Dr. Peter Baker). Alternatively, as designated in 
the text, omental samples from children with normal renal function (control), CKD5 at the time of PD start 
and PD were obtained from the International Pediatric Biopsy Registry (www.clinicaltrials.gov NCT01893710). 
The groups were age-matched. All patients received neutral pH, low GDP PD fluids. Peritonitis was caused by 
Staphylococcus aureus (6 cases), Enterobacter species (1 case), Corynebacterium species (1 case), and 2 cases were 
culture-negative.
qRT-PCR. Total RNA was extracted from using the RNeasy Mini Kit (Qiagen). RNA was quantified based on 
absorbance at 260 nm and reverse transcribed into complementary (c)DNA with the Verso cDNA Synthesis Kit 
(Thermo Fisher Scientific, Waltham, MA) in 20 µl total volume. The cDNA was diluted with 40 µl sterile water, 
and 2 µl was used as template in qPCR reactions using SybrGreen detection and the following gene-specific prim-
ers: RNASE3 Forward 5′-AGA GAC TGG GAA ACA TGG-3′; RNASE3 Reverse 5′-GAT AAT TGT TAA TTG 
CCC GC-3′; RNASE6 Forward 5′-AGC CCC AAC ACT GAG ACC AGA AAA-3′; RNASE6 Reverse 5′-GGT 
GGC AGT TGT GCC GAC GA-3′; RNASE7 Forward 5′-AAG ACC AAG CGC AAA GCG AC-3′, and RNASE7 
Reverse 5′-GCA GGC TAT TTT GGG GGT CT-3′. Exclusion of reverse transcriptase during cDNA synthesis 
resulted in undetectable amplification, attesting to amplicon derivation from cDNA rather than contaminating 
genomic DNA. Positive controls consisted of bone marrow cDNA (RNASE3, RNASE6) and skin cDNA (RNASE7). 
Amplicons were cloned into pCR4 (Invitrogen, Carlsbad, CA) and bidirectionally sequenced. Standard curves for 
each amplicon were included with each set of reactions. Absolute transcript levels were expressed per 10 ng total 
input RNA23.
eLIsA. Commercial ELISAs were used for detection of RNase 3 (MBL International, Woburn, MA), RNase 6 
(Cloud-Clone), and RNase 7 (Cloud-Clone) in cell-free supernatants of peritoneal fluid. The supplied protocol 
was followed without modification. Samples were run in triplicate. Only values falling on the standard curve were 
used. The lower limit of detection was 125 pg/ml (RNase 3), 6.5 pg/ml (RNase 6), and 540 pg/ml (RNase 7).
Cytology and Immunocytochemistry. 50,000 cells were subject to cytocentrifugation. Slides were 
differentially stained (Kwik-Diff, ThermoFisher Scientific, Waltham, MA). For immunostaining, cells were 
permeabilized with 100% cold acetone for 2 minutes at room temperature. Slides were washed in phosphate 
buffered saline (PBS) with 0.05% Tween-20, treated 10 minutes with Superblock (Scytek, Logan, UT), and incu-
bated with primary antibodies overnight at room temperature: α-RNase3 (Abcam), α-RNase6 (Cloud-Clone), 
α-RNase7 (Sigma), α-CD66b (Stem Cell Technologies, Vancouver, BC), α-CD68 (Stem Cell Technologies), and 
α-Cytokeratin (CAM5.2, Becton Dickinson, Franklin Lakes, NJ). The next day, slides were washed, hybridized 
with Alexafluor 488 and Alexafluor 595 conjugated secondary antibodies (Jackson ImmunoResearch, West Grove, 
PA) for 90 minutes at room temperature, washed again, and cover slipped in mounting medium with DAPI for 
nuclear visualization (Vector Labs, Burlingame, CA). Slides were visualized using an Olympus BX51 microscope 
and CX9000 camera. Controls consisted of irrelevant primary and secondary only conditions.
Immunohistochemistry. Three or four micron sections of human omentum were subject to immunohisto-
chemistry using the aforementioned primary antibodies, as previously described23. To quantify RNase 3 reactive 
cells in omentum, slides were scanned at 20x magnification (NanoZoomer, Hamamatsu, Japan) and analyzed with 
Aperio ImageScope software (Leica, Wetzlar, Germany). Large vessels were excluded. The Positive Pixel Count 
Algorithm was used to determine the fraction of RNase3+ cells among total cell nuclei, expressed as a percentage.
statistical analysis. ROC curves, area under the curve, and indicated statistical analyses were performed 
using GraphPad (La Jolla, CA). In all cases, p < 0.05 was considered statistically significant.
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